Literature DB >> 30206969

Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c-Myc/hypoxia-inducible factor-1 alpha pathway.

Zhang Weili1, Liu Zhikun2, Wang Jianmin3, Tian Qingbao3.   

Abstract

Acquired radioresistance is a major clinical obstacle in the treatment of esophageal cancer (EC). Ubiquitin-specific protease 28 (USP28) has been implicated in tumor growth in various cancer types. However, the role of USP28 and its underlying mechanisms of radioresistance in EC remain unknown. In the current study, we found that USP28 and c-Myc levels were upregulated in EC tissues and EC cell lines. The mRNA expression levels of USP28 and c-Myc were increased in the radioresistant human EC cell line (ECA109R) compared with those in ECA109 cells. In addition, the expression levels of USP28 and c-Myc were increased with increase in culture time after irradiation. Meanwhile, overexpression of USP28 decreased the radiosensitivity of ECA109 cells. In contrast, USP28 knockdown enhanced the radiosensitivity of ECA109R cells. Moreover, USP28 positively regulated the protein level of c-Myc, and c-Myc negatively regulated the radiosensitivity of ECA109 and ECA109R cells. Furthermore, c-Myc reversed the inhibitory effect of USP28 on the radiosensitivity of EC cells. Additionally, c-Myc enhanced the accumulation of hypoxia-inducible factor-1 alpha (HIF-1α) at the posttranscriptional level, and the reinforcing effect of c-Myc silencing on the radiosensitivity of EC cells could be reversed by HIF-1α overexpression. Besides, knockdown of USP28 blocked the effect of c-Myc on activation of ataxia telangiectasia-mutated/ataxia telangiectasia and Rad3-related DNA damage checkpoint after irradiation. In conclusion, knockdown of USP28 enhanced the radiosensitivity of EC cells by destabilizing c-Myc and enhancing the accumulation of HIF-1α. Therefore, USP28 may serve as a novel therapeutic target to overcome EC radioresistance.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  USP28; c-Myc; esophageal cancer; hypoxia-inducible factor-1 alpha; radiosensitivity

Year:  2018        PMID: 30206969     DOI: 10.1002/jcb.27305

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  5 in total

Review 1.  Advances in the Development Ubiquitin-Specific Peptidase (USP) Inhibitors.

Authors:  Shiyao Chen; Yunqi Liu; Huchen Zhou
Journal:  Int J Mol Sci       Date:  2021-04-27       Impact factor: 5.923

Review 2.  Long non-coding RNA PVT1 interacts with MYC and its downstream molecules to synergistically promote tumorigenesis.

Authors:  Ke Jin; Shufei Wang; Yazhuo Zhang; Mengfang Xia; Yongzhen Mo; Xiaoling Li; Guiyuan Li; Zhaoyang Zeng; Wei Xiong; Yi He
Journal:  Cell Mol Life Sci       Date:  2019-07-15       Impact factor: 9.261

Review 3.  Molecular Crosstalk Between MYC and HIF in Cancer.

Authors:  Yanping Li; Xiao-Xin Sun; David Z Qian; Mu-Shui Dai
Journal:  Front Cell Dev Biol       Date:  2020-11-05

Review 4.  USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.

Authors:  Cristian Prieto-Garcia; Ines Tomašković; Varun Jayeshkumar Shah; Ivan Dikic; Markus Diefenbacher
Journal:  Cells       Date:  2021-10-04       Impact factor: 6.600

Review 5.  The role of ubiquitination and deubiquitination in cancer metabolism.

Authors:  Tianshui Sun; Zhuonan Liu; Qing Yang
Journal:  Mol Cancer       Date:  2020-10-01       Impact factor: 27.401

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.